Medical Laser System Market Size, Share, Growth and Forecast to 2023

Medical Laser System Market

The medical laser system market is growing at a considerable rate, due to increased awareness of medical aesthetics, growing number of patients using advanced laser based treatments, and rapid rise in age related ophthalmic disorders. Rise in disposable incomes in developing economies and increased demand for laser treatment in emerging economies have provided ample opportunities to the growth of medical laser system market to grow in the coming years.

Explore more about Medical laser System Market: https://www.psmarketresearch.com/market-analysis/medical-laser-system-market

North America leads the medical laser system market, due to the rising incidences of chronic diseases such as diabetes and obesity. Asia-Pacific is growing with the highest rate, due to unaddressed need for medical treatment in developing countries such as, India and China in the region.

Medical Laser Systems are used to produce a monochromatic beam of light containing a specific wavelength and it is strongly concentrated. The demand for lasers in the field of medicine is rising rapidly, due to the flexibility of its light. Power, pulsed or continuous wave operation, and wavelength of laser, define the characteristics of laser light.

On the basis of products, the medical laser system market can be categorized into solid state laser systems, diode laser systems, dye laser systems and gas laser systems. The diode laser system leads the medical laser system market and is expected to grow in the coming years, due to its varied medical applications such as, numerous aesthetic treatments and photodynamic therapy. Solid state laser system is expected to grow with the highest rate, due to its numerous modifications having specific applications in medical related treatments such as, periodontology, tattoo removal, skin treatment and vein removal.

Gas laser systems include metal vapor lasers, excimer lasers, argon lasers, helium-neon lasers, krypton lasers and CO2 lasers. Solid state laser systems include, erbium yttrium aluminum garnet lasers, alexandrite lasers, holmium yttrium aluminum garnet lasers, ruby lasers, potassium titanyl phosphate and neodymium yttrium aluminum garnet lasers.

Request Table of Contents: https://www.psmarketresearch.com/market-analysis/medical-laser-system-market/toc-sample

Meeting the need for laser treatment globally in several applications such as, cardiovascular diseases, dermatology diseases, and technological advancements are the key strategies for the competitors in the medical laser system market. Some of the major competitors in the medical laser system market are Cardiogenesis Corporation, Bausch & Lomb Holdings, Inc., Photomedex, Inc., IRIDEX Corp., American Medical Systems, Inc., Syneron Medical Ltd., Lumenis Ltd., Alcon Laboratories, Spectranetics Corporation, Inc., and Biolase Inc.

Advertisements

Anti-Aging Market Analysis, Size, Share, Growth and Forecast to 2025

Anti-Aging Market

According to the study, the global anti aging market is expected to witness 7.7% CAGR during 2017 – 2025. Technological advancements, increase in volume of anti-aging procedures, growing aging population and increase in disposable income have been driving the global anti-aging market. The market is further expected to gain revenue due to increase in anti-aging awareness campaigns. For instance, EuroMediCom plans to organize the 15th Aesthetic & Anti-Aging Medicine World Congress from 6th April to 8th April, 2017, in Monaco. Furthermore, EuroMediCom is also going to organize the 4th AMWC Latin America- Aesthetic & Anti-Aging Medicine World Congress from 16th November to 18th November, 2017, in Colombia, South America. EuroMediCom promotes future medical sciences, particularly those related to aging and aesthetics.

Geographically, North America has been the largest anti-aging market, with the U.S. being the largest contributor to the regional market. Increasing volume of plastic surgeries and growing geriatric population in the region are the key growth drivers for the North American anti-aging market. As reported by the American Society for Aesthetic Plastic Surgery (ASAPS), American spent more than $13.5 billion on cosmetic procedures in 2015. It further reported that 1,912,468 surgical procedures and 10,879,909 non-surgical procedures were performed. It was also reported that liposuction was the most popular surgical procedure in 2015 with about 396,048 procedures performed.

Europe is also a key market for anti-aging products and it is anticipated to witness considerable growth during the forecast period. Increase in product approvals and aging population are driving the European market. According to International Society of Aesthetic Plastic Surgery (ISAPS), some of the popular surgical anti-aging surgical procedures in European countries in 2015 included breast augmentation, liposuction, eyelid surgery, and abdominoplasty.

Some of the other key players in the market include The Proctor & Gamble Company, Beiersdorf AG, Allergan Plc., The Estee Lauder Companies Inc., Nu Skin Enterprises, Inc., Coty Inc., Cynosure, Inc., Lumenis Ltd., Syneron Medical Ltd., Photomedex Inc., Orlane, Personal Microderm and Alma Lasers Ltd.

News Courtesy : P&S Market Research

Sterilization Equipment and Disinfectants Market Size, Share, Development and Forecast to 2023

Sterilization Equipment and Disinfectants Market

The global sterilization equipment and disinfectants market is growing significantly due to technological advancement such as innovation of E-beam and gamma beam in the industry. Sterilization equipment and disinfectants are elemental procedures used to eliminate or control various infectious agents, such as virus and bacteria. The increasing use of these in hospitals, clinics, and laboratories, to reduce the hospital acquired infection, support the growth of the sterilization equipment and disinfectants market.

Explore Report at:  https://www.psmarketresearch.com/market-analysis/sterilization-equipment-and-disinfectants-market

Massive unexplored market of sterilization equipment and disinfectants in developing economies are creating ample opportunities for the sterilization equipment and disinfectants market to grow at a considerable rate in the coming years. The advanced R&D facilities and new product developments by the companies are further supporting the growth of sterilization equipment and disinfectants industry.

On the basis of products, the sterilization equipment market can be categorized as heat sterilizers, low temperature sterilizers, radiation sterilization and filtration sterilization. The heat sterilization equipment leads the sterilization equipment and disinfectants market due to its user friendly and secure nature; whereas, the low temperature sterilizers are expected to grow at the fastest rate in the coming years due to its complex and advanced sterilizing efficiency for medical devices, such as endoscopes. Heat sterilization is further categorized as autoclave, hot air oven, and others. Low temperature sterilizers include ethylene oxide sterilization, hydrogen peroxide gas plasma, and vaporized hydrogen peroxide. Whereas, the radiation sterilization includes gamma sterilization, electron beams sterilization, and others.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/sterilization-equipment-and-disinfectants-market/toc-sample

Some of the companies operating in the sterilization equipment and disinfectants market are 3M, Cantel Medical Corporation, Belimed AG, TSO3 Inc., Getinge Group, CISA Group, Advanced Sterilization Products Services Inc., Synergy Health Plc, STERIS Corporation, Kimberley-Clark Corporation, Nordion Inc., and Sakura SI Co.Ltd.

Active Pharmaceutical Ingredients Market Size, Share, Growth and Forecast to 2023

Active Pharmaceutical Ingredients Market

The global active pharmaceutical ingredient market is growing significantly due to patent expiry of biologic drugs in the industry. Patent expiry of blockbuster drugs has boosted the demand for low cost substitutes, which further increases the demand for active pharmaceutical ingredients in the industry. Moreover, increasing investment into biosimilars is expected to support the growth of the market in the coming years.

Explore Report at: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredients-market

Massive unexplored market in active pharmaceutical ingredient industry of developing economies are creating ample opportunities for the active pharmaceutical ingredient market to grow at a considerable rate in the coming years. Active pharmaceutical ingredients are the primary components of manufacturing effective and safe essential drugs. The advanced research and development facilities of the companies are supporting to address the demand of the active pharmaceutical ingredient industry.

On the basis of type of manufacturers of active pharmaceutical ingredient, the market can be categorized as in-house active pharmaceutical ingredient manufacturing and active pharmaceutical contract manufacturing. The in-house active pharmaceutical ingredient manufacturing leads the active pharmaceutical ingredient market by type of manufacturer category. In addition, the in-house manufacturing is continuously witnessing decline in the segment due to reduced profitability and high research and development cost. On the basis of type of active pharmaceutical ingredient, the market can be categorized as biological active pharmaceutical ingredients, and synthetic chemical active pharmaceutical ingredients. Moreover, on the basis of type of drugs, the market can be categorized as generic prescription drugs, over-the-counter (OTC) drugs, and branded or innovative prescription drugs.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/active-pharmaceutical-ingredients-market/toc-sample

Geographically, North America will be leading the global active pharmaceutical ingredient market in the coming years due to increasing research and development programs in the field of drugs and medical science. Asia-Pacific is the fastest growing region in the global active pharmaceutical ingredient market. The major reasons for the fastest growth of the market in the region are increasing healthcare expenditure, large pool of patients, and presence of large pool of generic medicine producers in the region. Moreover, the active pharmaceutical ingredient market is growing due to increasing awareness of lifestyle associated diseses in the emerging countries, such as India and China, of Asia-Pacific region.

Some of the companies operating in the active pharmaceutical ingredient market are Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories, Actavis Plc, Hospira Inc., Boehringer Ingelheim Group, Lonza Group, Cambrex Corporation, Novartis International AG, BASF SE, Pfizer, Inc., Mylan, Inc., Watson Pharmaceutical Inc., and WuXi Apptec.

Disinfectors Market Size, Share, Development and Demand Forecast to 2023

Disinfectors Market

Owing to the fact that cleaning and sanitation are vital for safety in the healthcare industries, the global market for disinfectants is driven by increased focus on hygiene and growing concerns over the spread of infectious diseases both at home and in public places. Rising demands in the food, beverage and healthcare industries is driving the global disinfectors market. Disinfectant chemicals are also becoming more common as an ingredient in various conventional and industrial cleaning products.

Explore Report at: https://www.psmarketresearch.com/market-analysis/disinfectors-market

Disinfectors are used for destroying pathogens for controlling infection.
Disinfection is an essential procedure that is performed for infection control in households and in healthcare facilities such as clinics, hospitals, elder care institutes and laboratories, using disinfectors and other infection control equipment such as sterilizers. Disinfectors are used to disinfect various medical instruments such as bedpans, surgical instruments, urine bottles and endoscopes. Disinfection is the process of destroying pathogenic organisms or rendering them inert. Hence, it ensures the hygiene condition of medical appliances that are used while providing medical services to people by healthcare workers.

The global disinfectant market can be categorized on the basis of disinfectors by product type, and disinfectors by applications. Based on disinfectors by product type, the global market for disinfectors is divided into washer, flusher and endoscope reprocessor. The washer is further divided into a single chamber (single door and double door) and multi chamber. On the basis of application, the global disinfectors market is classified into elder care, hospitals and clinics, and pharmaceuticals and life sciences.

Request for table of Content at: https://www.psmarketresearch.com/market-analysis/disinfectors-market/toc-sample

The rise in number of healthcare infrastructure in developing countries is one of the major trends in the disinfectors market. The large population in developing countries has opened up a large patient pool which eventually gives a rise in disposable income. The favorable economic conditions in most of the developing countries are propelling the infrastructural growth by establishing more medical care facilities and hospitals. Liquid products and aerosol are the most commonly used surface decontaminators, though a significant number of hospitals are employing UV disinfection systems as an surplus measure. Hence, another trend in the disinfectors market is the use of ultraviolet (UV) disinfectors as UV radiation inactivates micro-organisms by destroying the nucleic acids in viruses and bacteria.

Owing to the rise in number of chronic diseases, epidemic diseases such as H1N1 and aging population, North America dominates the disinfectors market followed by Europe.. Some of the major competitors in the global disinfectors market are Advanced Sterilization Products Division Ethicon US, LLC, Getinge AB, OLYMPUS CORPORATION and STERIS Corporation. Other prominent competitors in the market include ACTAVIS, American Biotech Labs, LLC, Amrep Inc, CareFusion Corporation, CCP Industries , Bio-Cide International, Inc., BIOTECHMEDICS US., Cantel Medical, Colgate-Palmolive Company., Swisher International, Inc., Diversey Inc.and many more.

 

Hypodermic Needle Market Analysis, Size, Development and Forecast to 2022

Hypodermic Needle Market

The global hypodermic needles market is expected to grow at a CAGR of 7.4% during 2016 – 2022. The growth of the global market is largely driven by the high demand for vaccines and increasing compliance of safety needles. High prevalence of needle stick injuries during drug administration is a key concern for healthcare providers across the globe. Improper disposal of syringe and needles is creating the demand for advanced safety mechanisms in hypodermic needles. Globally, approximately 16 billion injections are administered every year as per the World Health Organization (WHO); however, all the syringes and needles are not properly disposed of. Therefore, several benefits of safety needles such as ease of use during injection and safe delivery of drug or medication are increasing their popularity among healthcare providers.

Explore Report with Detailed TOC on “Global Hypodermic Needle Market” at: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market

Healthcare providers along with patients are getting aware about safety in drug delivery through syringes. This has created huge traction in the global market for developing advanced safety hypodermic needles with automatic features. Some of the other factors driving the growth of the global market include increasing prevalence of chronic and lifestyle associated diseases, and geriatric population. Increasing adoption of hypodermic needles in emerging economies is expected to create ample growth opportunities for the global market. However, alternative drug delivery method and high cost of hypodermic needles are the key barriers for the growth of the global market.

North America led the global hypodermic needle market in terms of size in 2015, owing to the increasing awareness of safe injectable technology, and increasing prevalence of chronic and lifestyle associated diseases. The U.S. contributed largest revenue to the North American as well as the global hypodermic needle market. The country is expected to remain the largest market for hypodermic needle globally during the forecast period.

Request For Sample Pages: https://www.psmarketresearch.com/market-analysis/hypodermic-needles-market/report-sample

Some of the players operating in the global market include Vygon S.A., Catalent, Inc., Terumo Corporation, Retractable Technologies, Inc., Connecticut Hypodermics, Inc., MedPro Safety Products Inc., B. Braun Melsungen AG, Albert David Ltd., Becton, Dickinson and Company, and Medtronic plc.

Ocular Pain Treatment Market Share, Development, Growth and Demand Forecast to 2023

The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.

The pharmaceutical companies are actively involved in the research and development of drugs for ocular pain. Loteprednol etabonate, a Mucus-Penetrating Particle platform technology based Phase III clinical trial drug of Kala Pharmaceuticals, Inc., is nanotechnology based products for the treatment of ocular pain.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market

Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye.  Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.

A large number of pharmaceutical companies are constantly working for the research and development of ocular pain treatment. However, certain factors such as high treatment cost, less awareness about the eye disease among population and lack of favorable government policy are the key factors hindering the growth of the global market during the forecast period.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market/toc-sample

Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc.,  Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.

Personalized Medicine Market – Pipeline Analysis, Growth and Demand Forecast to 2023

Personalized Medicine Market

The global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.

Explore Full Report Description with Detailed TOC at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market

The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.

National Cancer Institute, a part of the U.S. National Institutes of Health (NIH) defined personalized medicine as a form of medicine that uses information about a person’s genes, proteins and environment to prevent, diagnose and treat disease. In cancer, personalized medicine uses specific information about a person’s tumor to help diagnose, plan treatment, find out how well treatment is working, or make a prognosis. Personalized medicine uses targeted therapies to treat specific types of cancer cells, such as HER2-positive breast cancer cells, and to develop tumor marker for the diagnosis of cancer.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market/toc-sample

Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.

Uterine Fibroid Treatment Market Size, Share, Growth and Forecast to 2023

The global uterine fibroid treatment market is witnessing considerable growth due to increasing female geriatric population, increasing healthcare expenditure, increasing prevalence of obesity, launch of technologically advanced fibroid treatment products and growing popularity of minimally invasive treatments   minimally invasive treatments. Moreover, growing prevalence of hormonal disorders or hormonal imbalance leading to fibroid formation is supporting the growth of the market. The increasing adoption of uterine fibroid treatment across the globe, owing to increasing incidence of cancer is also driving the growth of the market.

Explore Report at: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market

The rapid growth in emerging economies and technological advancement in fibroid treatment with presence of minimally invasive treatment options is expected to create opportunities for the manufacturers of uterine fibroid treatment products. However, high cost of uterine fibroid treatment and presence of alternative treatment options are the key factors hampering the growth of the global market.

The increasing female aging population is propelling the growth of the global uterine fibroid treatment market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynecological problems, such as abnormal uterine bleeding, hormonal imbalance, and irregular menstrual cycle as compared to adults, which is fueling the demand of the global fibroid treatment market.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/uterine-fibroid-treatment-market/toc-sample

The key players operating in the global market are Boston Scientific Corporation, CooperSurgical, Inc., Karl Storz, Halt Medical, Inc., Merit Medical Systems, LiNA Medical USA, Olympus Corporation, and Richard Wolf GmbH.

Congestive Heart Failure Therapeutics Pipeline Analysis, 2017 – Clinical Trials and Results, Collaboration and Other Developments

Prevalence of congestive heart failure is witnessed to have increased, especially in Asia-Pacific and American region, due to rapid change in lifestyle of people, which in turn is results in various lifestyle diseases such as diabetes and high blood pressure. Additionally, other factors such as, sedentary nature of job, high cholesterol diet intake, lack of exercise, pollution, are also contributing to the increasing incidence of congestive heart failure, across the globe. The therapeutic pipeline for congestive heart failure is expected to grow in the next few years on account of increasing participation of various multinational pharmaceutical companies for the development of novel drugs, to be used in the treatment of congestive heart failure. According to the latest WHO report, it is estimated that there are around 26 million people suffering from problem of congestive heart failure, worldwide, with nearly 5.8 million cases having been registered in the U.S. only.

Explore Report at: https://www.psmarketresearch.com/market-analysis/congestive-heart-failure-therapeutics-pipeline-analysis

Congestive heart failure is a chronic progressive condition which affects the pumping power of the heart muscle. It is the stage where fluids build up around the heart and leads to inefficient pumping of blood to various organs of the body. Heart has four chambers; the upper half of the heart has two atria and the lower half of the heart has two ventricles. The ventricles pump blood to our body organs and tissues and the atria receives blood as it circulates back from the rest of the body. Insufficient supply of blood from the ventricles, to the organs in the body, leads to congestive heart failure. Of the four different classes of congestive heart failure, in class I and II, the individuals do not experience any major symptoms, and the problem of congestive heart failure can be controlled by making lifestyle changes, meditation and exercise. However, in the class III and IV stages, the patient’s condition is severe and the problem can only be controlled through proper treatment. There are many symptoms of congestive heart failure including irregular heartbeat, fatigue, shortness of breath, edema, chest pain, wheezing, fainting and weight gain.

Request for Table of Content at: https://www.psmarketresearch.com/market-analysis/congestive-heart-failure-therapeutics-pipeline-analysis/toc-sample

Some of the companies having a pipeline of congestive heart failure therapeutics include Glaxosmithkline plc, Amgen Inc., Merck Sharp & Dohme Co, Bayer Pharmaceuticals, Novartis Pharmaceuticals, Janssen Research and Development, LLC, Scios, Inc., Quantum Genomics SA, AstraZeneca plc, Bristol-Myers Squibb etc.